QUINOLINIC ACID AND KYNURENINE PATHWAY MET NON-INFLAMMATORY NEUROLOGICAL DISEASE

Brain 115, 1249-1273 DOI: 10.1093/brain/115.5.1249

Citation Report

#	Article	IF	CITATIONS
2	Human macrophages convert <scp>l</scp> -tryptophan into the neurotoxin quinolinic acid. Biochemical Journal, 1992, 283, 633-635.	1.7	305
3	Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience, 1992, 51, 25-39.	1.1	197
4	Poliovirus induces indoleamineâ€2,3â€dioxygenase and quinolinic acid synthesis in macaque brain. FASEB Journal, 1992, 6, 2977-2989.	0.2	98
5	Kynurenine Pathway Enzymes in Brain: Responses to Ischemic Brain Injury Versus Systemic Immune Activation. Journal of Neurochemistry, 1993, 61, 2061-2070.	2.1	110
6	Quinolinate potentiates the neurotoxicity of excitatory amino acids in hypoxic neuronal tissue in vitro. Brain Research, 1993, 617, 76-80.	1.1	27
7	Increased levels of the excitotoxin quinolinic acid in spinal cord following contusion injury. Brain Research, 1993, 632, 314-316.	1.1	37
8	Antibodies to quinolinic acid reveal localization in select immune cells rather than neurons or astroglia. Brain Research, 1993, 623, 337-340.	1.1	39
9	Neuro-AIDS: primate lentivirus infection and the brain. Advances in Neuroimmunology, 1993, 3, 97-127.	1.8	3
10	Quinolinic Acid and Inflammation. Annals of the New York Academy of Sciences, 1993, 679, 211-216.	1.8	17
11	A mechanism of quinolinic acid formation by brain in inflammatory neurological disease: Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain, 1993, 116, 1425-1450.	3.7	164
12	Induction of pterin synthesis is not required for cytokine-stimulated tryptophan metabolism. Biochemical Journal, 1993, 295, 543-547.	1.7	11
13	Impaired motor-skill learning, slowed reaction time, and elevated cerebrospinal-fluid quinolinic acid in a subgroup of HIV-infected individuals Neuropsychology, 1993, 7, 149-157.	1.0	43
14	Quinolinic Acid in the Cerebrospinal Fluid of Children with Symptomatic Human Immunodeficiency Virus Type 1 Disease: Relationships to Clinical Status and Therapeutic Response. Journal of Infectious Diseases, 1993, 168, 1380-1386.	1.9	75
15	4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-1 ³ -stimulated monocytes (THP-1 cells). Biochemical Journal, 1993, 291, 11-14.	1.7	98
16	Inflamed debate over neurotoxin. Science, 1993, 259, 25-26.	6.0	7
17	Laboratory Evaluations in HIV-1-Associated Cognitive/Motor Complex. Psychiatric Clinics of North America, 1994, 17, 91-123.	0.7	8
18	Serotonin and Human Myoclonus. Archives of Neurology, 1994, 51, 605.	4.9	56
19	Lyme disease: a neuropsychiatric illness. American Journal of Psychiatry, 1994, 151, 1571-1583.	4.0	189

#	Article	IF	CITATIONS
20	Quantification ofL-tryptophan andL-kynurenine by liquid chromatography/electron capture negative ion chemical ionization mass spectrometry. Biological Mass Spectrometry, 1994, 23, 27-32.	0.5	12
21	Antibodies to quinolinic acid and the determination of its cellular distribution within the rat immune system. Cell and Tissue Research, 1994, 278, 461-469.	1.5	57
22	Quinolinate-induced injury is enhanced in developing rat brain. Developmental Brain Research, 1994, 83, 224-232.	2.1	32
23	Quinolinic acid immunoreactive cells in the choroid plexus, leptomeninges and brain vasculature of the immune-stimulated gerbil. Journal of Neuroimmunology, 1994, 54, 69-73.	1.1	20
24	Kynurenine Pathway Metabolites in Cerebrospinal Fluid and Serum in Complex Partial Seizures. Epilepsia, 1994, 35, 251-257.	2.6	54
25	Elevation of the neurotoxin quinolinic acid occurs following spinal cord trauma. Brain Research, 1994, 633, 348-352.	1.1	63
26	4-chloro-3-hydroxyanthranilate inhibits quinolinate production in the rat hippocampus in vivo. Brain Research Bulletin, 1994, 33, 513-516.	1.4	20
27	Effects of chronic zidovudine administration on CNS function and virus burden after perinatal SIV infection in rhesus monkeys. Advances in Neuroimmunology, 1994, 4, 233-237.	1.8	7
28	6-Chloro-d,l-tryptophan, 4-chloro-3-hydroxyanthranilate and dexamethasone attenuate quinolinic acid accumulation in brain and blood following systemic immune activation. Neuroscience Letters, 1994, 178, 211-215.	1.0	27
29	Quinolinic Acid in Neurological Disease: Opportunities for Novel Drug Discovery. Advances in Pharmacology, 1994, 30, 85-127.	1.2	39
30	Temporal and spatial changes of quinolinic acid immunoreactivity in the immune system of lipopolysaccharide-stimulated mice. Journal of Leukocyte Biology, 1995, 57, 199-206.	1.5	34
31	An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease. Journal of Neural Transmission, 1995, 102, 67-73.	1.4	15
32	Rapid appearance of ?-amyloid precursor protein immunoreactivity in glial cells follwing excitotoxic brain injury. Acta Neuropathologica, 1995, 89, 23-28.	3.9	50
33	Hypoxia, excitotoxicity, and neuroprotection in the hippocampal slice preparation. Journal of Neuroscience Methods, 1995, 59, 129-138.	1.3	52
34	HIV-gp120 activates large-conductance apamin-sensitive potassium channels in rat astrocytes. American Journal of Physiology - Cell Physiology, 1995, 268, C1440-C1449.	2.1	30
35	Neurocytotoxity of quinolinic acid in human brain cultures. Journal of NeuroVirology, 1995, 1, 375-380.	1.0	39
36	Increased Human Immunodeficiency Virus (HIV) Type 1 DNA Content and Quinolinic Acid Concentration in Brain Tissues from Patients with HIV Encephalopathy. Journal of Infectious Diseases, 1995, 172, 638-647.	1.9	55
37	Quinolinic acid accumulation and functional deficits following experimental spinal cord injury. Brain, 1995, 118, 735-752.	3.7	100

#	Article	IF	CITATIONS
38	The relationship between plasma and brain quinolinic acid levels and the severity of hepatic encephalopathy. Gastroenterology, 1995, 108, 818-823.	0.6	32
39	Cerebrospinal fluid levels of kynurenine pathway metabolites in patients with eating disorders: Relation to clinical and biochemical variable. Biological Psychiatry, 1995, 37, 512-520.	0.7	31
40	Spatial recognition memory deficits without notable CNS pathology in rats following herpes simplex encephalitis. Journal of the Neurological Sciences, 1995, 131, 119-127.	0.3	27
41	Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children. Journal of the Neurological Sciences, 1995, 133, 112-118.	0.3	59
42	Low-dose challenge by the NMDA receptor antagonist dizocilpine exacerbates the spatial learning deficit in entorhinal cortex-lesioned rats. Behavioural Brain Research, 1995, 67, 255-261.	1.2	14
43	Systemic dl-Kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats. Neuropharmacology, 1996, 35, 23-28.	2.0	47
44	Decreased plasma tryptophan in pregnancy. Obstetrics and Gynecology, 1996, 88, 47-50.	1.2	134
45	Increased kynurenic acid levels and decreased brain kynurenine aminotransferasei in patients with down syndrome. Life Sciences, 1996, 58, 1891-1899.	2.0	74
46	Quinolinic acid neurotoxicity: In vivo increased copper and manganese content in rat corpus striatum after quinolinate intrastriatal injection. Toxicology Letters, 1996, 87, 113-119.	0.4	15
47	Early increases in TNF-α, IL-6 and IL-1β levels following transient cerebral ischemia in gerbil brain. Neuroscience Letters, 1996, 206, 149-152.	1.0	251
48	Expression of Inflammatory Cytokines and Inducible Nitric Oxide Synthase in Brains of SIV-Infected Rhesus Monkeys: Applications to HIV-Induced Central Nervous System Disease. Molecular Medicine, 1996, 2, 27-37.	1.9	70
49	Study of Receptor-Mediated Neurotoxins Released by HIV-1-Infected Mononuclear Phagocytes Found in Human Brain. Journal of Neuroscience, 1996, 16, 3139-3153.	1.7	165
50	Neurobehavioral Manifestations of Symptomatic HIV-1 Disease in Children: Can Nutritional Factors Play a Role?. Journal of Nutrition, 1996, 126, 2651S-2662S.	1.3	9
51	Human microglia convert <scp>l</scp> -tryptophan into the neurotoxin quinolinic acid. Biochemical Journal, 1996, 320, 595-597.	1.7	280
52	Immunocytochemical localization of the endogenous neuroexcitotoxin quinolinate in human peripheral blood monocytes/macrophages and the effect of human T-cell lymphotropic virus type I infection Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 1636-1641	3.3	17
53	AIDS dementia and HIV-1-induced neurotoxicity: Possible pathogenic associations and mechanisms. Journal of Biomedical Science, 1996, 3, 389-414.	2.6	33
54	Decreased plasma ratio of tryptophan to competing large neutral amino acids in human immunodeficiency virus type 1 infected subjects: Possible implications for development of neuro-psychiatric disorders. Journal of Neural Transmission, 1996, 103, 157-164.	1.4	13
55	3 Neurotransmitter dynamics in cerebral ischaemia. Bailliere's Clinical Anaesthesiology, 1996, 10, 427-444.	0.2	0

#	Article	IF	CITATIONS
56	Animal models of mental retardation: An overview. Mental Retardation and Developmental Disabilities Research Reviews, 1996, 2, 185-187.	3.5	3
57	Primate lentivirus-associated encephalopathy. Mental Retardation and Developmental Disabilities Research Reviews, 1996, 2, 257-263.	3.5	0
58	Increased quinolinate immunoreactivity in the peripheral blood monocytes/macrophages from SIVinfected monkeys. Journal of NeuroVirology, 1996, 2, 433-438.	1.0	21
59	Intrathecal Infusion of the Nitric Oxide Synthase InhibitorN-Methyll-Arginine after Experimental Spinal Cord Injury in Guinea Pigs. Journal of Neurotrauma, 1996, 13, 361-369.	1.7	11
60	Neuroinvasion by simian immunodeficiency virus coincides with increased numbers of perivascular macrophages/microglia and intrathecal immune activation. Journal of NeuroVirology, 1996, 2, 423-432.	1.0	148
61	Quinolinic Acid Production by Macrophages Stimulated with IFN-γ, TNF-α, and IFN-α. Journal of Interferon and Cytokine Research, 1997, 17, 589-595.	0.5	132
62	Increasedcâ€fosExpression in the Brain during Experimental Murine Cerebral Malaria: Possible Association with Neurologic Complications. Journal of Infectious Diseases, 1997, 175, 1480-1489.	1.9	17
63	Activated human microglia produce the excitotoxin quinolinic acid. NeuroReport, 1997, 8, 431-434.	0.6	184
64	Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochemical Journal, 1997, 326, 351-356.	1.7	205
65	Kynurenine pathway inhibition reduces neurotoxicity of HIV-1-infected macrophages. Neurology, 1997, 49, 1671-1681.	1.5	84
66	Quinolinic Acid Accumulation in Injured Spinal Cord: Time Course, Distribution, and Species Differences between Rat and Guinea Pig. Journal of Neurotrauma, 1997, 14, 89-98.	1.7	35
67	Effects of Nï‰-nitro-L-arginine and L-arginine on quinolinic acid-induced lipid peroxidation. Toxicology Letters, 1997, 93, 117-124.	0.4	38
68	Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophrenia Research, 1997, 24, 349-355.	1.1	343
69	Quinolinate Immunoreactivity in Experimental Rat Brain Tumors Is Present in Macrophages but Not in Astrocytes. Experimental Neurology, 1997, 144, 287-301.	2.0	42
70	A new function for a common fold: the crystal structure of quinolinic acid phosphoribosyltransferase. Structure, 1997, 5, 47-58.	1.6	101
71	Biochemical characteristics of γ-glutamyl transpeptidase in capillaries from entorhinohippocampal complex of quinolinate-lesioned rat brain. Molecular and Chemical Neuropathology, 1997, 32, 143-161.	1.0	11
72	Immuno-electron microscopy reveals that the excitotoxin quinolinate is associated with the plasma membrane in human peripheral blood monocytes/macrophages. Cell and Tissue Research, 1997, 290, 633-639.	1.5	7
73	Concentrations of quinolinic acid in cerebrospinal fluid measured by gas chromatography and electron-impact ionisation mass spectrometry. Biomedical Applications, 1997, 696, 53-58.	1.7	9

#	Article	IF	CITATIONS
74	Species Heterogeneity Between Gerbils and Rats: Quinolinate Production by Microglia and Astrocytes and Accumulations in Response to Ischemic Brain Injury and Systemic Immune Activation. Journal of Neurochemistry, 1997, 69, 1519-1529.	2.1	76
75	Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. Annals of Neurology, 1997, 42, 613-621.	2.8	109
76	Nitric oxide synthase inhibition prevents acute quinolinate-induced striatal neurotoxicity. Neurochemical Research, 1998, 23, 1297-1302.	1.6	64
77	Effects of electromagnetic fields on the levels of biogenic amine metabolites, quinolinic acid, and beta-endorphin in the cerebrospinal fluid of dairy cows. Neurochemical Research, 1998, 23, 1527-1531.	1.6	13
78	Altered tryptophan metabolism in mice with herpes simplex virus encephalitis: increases in spinal cord quinolinic acid. Neurochemical Research, 1998, 23, 661-665.	1.6	22
79	Effects of the 3-hydroxyanthranilic acid analogue NCR-631 on anoxia-, IL-1?- and LPS-induced hippocampal pyramidal cell lossin vitro. Amino Acids, 1998, 14, 263-269.	1.2	21
80	Differential effects of kynurenine and tryptophan treatment on quinolinate immunoreactivity in rat lymphoid and non-lymphoid organs. Cell and Tissue Research, 1998, 293, 525.	1.5	30
81	S-Aryl cysteine S,S-dioxides as inhibitors of mammalian kynureninase. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 133-138.	1.0	22
82	Increased expression of 3-hydroxyanthranilate 3,4-dioxygenase gene in brain of epilepsy-prone El mice. Molecular Brain Research, 1998, 58, 132-137.	2.5	8
83	Temporal and spatial changes of quinolinic acid immunoreactivity in the gerbil hippocampus following transient cerebral ischemia. Molecular Brain Research, 1998, 59, 50-57.	2.5	22
84	Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease. Neuroscience Letters, 1998, 241, 53-56.	1.0	87
85	Soluble Adhesion Molecules in CSF Are Increased in Children With Severe Head Injury. Journal of Neurotrauma, 1998, 15, 777-787.	1.7	79
86	Species Differences inl-Tryptophan–Kynurenine Pathway Metabolism: Quantification of Anthranilic Acid and Its Related Enzymes. Archives of Biochemistry and Biophysics, 1998, 358, 329-335.	1.4	74
87	Activated Immune System in Patients with Huntington's Disease. Clinical Chemistry and Laboratory Medicine, 1998, 36, 747-50.	1.4	78
88	The Effects of Human Immunodeficiency Virus in the Central Nervous System. Advances in Virus Research, 1998, 50, 1-47.	0.9	127
89	Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. Clinical Chemistry, 1998, 44, 858-862.	1.5	136
90	Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. FASEB Journal, 1998, 12, 881-896.	0.2	132
91	Regulation and Function of T-Cell-Mediated Immunity during <i>Toxoplasma gondii</i> Infection. Clinical Microbiology Reviews, 1998, 11, 569-588.	5.7	648

#	Article	IF	CITATIONS
92	Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Report, 1999, 4, 199-220.	1.4	186
93	Major Depression and Activation of The Inflammatory Response System. Advances in Experimental Medicine and Biology, 1999, 461, 25-46.	0.8	500
94	Dapsone prevents morphological lesions and lipid peroxidation induced by quinolinic acid in rat corpus striatum. Toxicology, 1999, 139, 111-118.	2.0	29
95	Progressive dendritic pathology in cynomolgus macaques infected with simian immunodeficiency virus. Neuropathology and Applied Neurobiology, 1999, 25, 10-18.	1.8	25
96	Nomega-nitro-L-arginine, a nitric oxide synthase inhibitor, antagonizes quinolinic acid-induced neurotoxicity and oxidative stress in rat striatal slices. Neurochemical Research, 1999, 24, 843-848.	1.6	36
97	Kynurenine metabolism in Alzheimer's disease. Journal of Neural Transmission, 1999, 106, 165-181.	1.4	202
98	The Role of Excitotoxicity in Neurodegenerative Disease. , 1999, 81, 163-221.		655
99	Tryptophan metabolism in pregnant sheep: Increased fetal kynurenine production in response to maternal tryptophan loading. American Journal of Obstetrics and Gynecology, 1999, 181, 1452-1460.	0.7	21
100	Quinolinic acid, α-picolinic acid, fusaric acid, and 2,6-pyridinedicarboxylic acid enhance the Fenton reaction in phosphate buffer. Chemico-Biological Interactions, 1999, 118, 201-215.	1.7	49
101	Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. European Journal of Pharmacology, 1999, 375, 87-100.	1.7	282
102	An Hplc Method to Determine Tryptophan and Kynurenine in Serum Simultaneously. Advances in Experimental Medicine and Biology, 1999, 467, 827-832.	0.8	21
103	Degradation of Tryptophan in Patients with Systemic Lupus Erythematosus. Advances in Experimental Medicine and Biology, 1999, 467, 571-577.	0.8	30
104	Cytokines, Stress, and Depression. Advances in Experimental Medicine and Biology, 1999, , .	0.8	17
105	Conditioned Immune Response to Interferon-Î ³ in Humans. Clinical Immunology, 1999, 90, 173-181.	1.4	43
106	Convection-enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates. Journal of Neurosurgery, 1999, 91, 294-302.	0.9	67
107	Evidence for Increased de Novo Synthesis of NAD in Immune-Activated RAW264.7 Macrophages: A Self-Protective Mechanism?. Archives of Biochemistry and Biophysics, 1999, 372, 1-7.	1.4	61
108	Interferon response heterogeneity: activation of a pro-inflammatory response by interferon α and β. A possible basis for diverse responses to interferon β in MS. Journal of Leukocyte Biology, 1999, 65, 439-443.	1.5	16
109	The SIV-infected rhesus monkey model for HIV-associated dementia and implications for neurological diseases. Journal of Leukocyte Biology, 1999, 65, 466-474.	1.5	31

ARTICLE IF CITATIONS # Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable 110 1.0 118 compartmentalization of infection. Aids, 1999, 13, 1051-1061. Tissue distribution of indoleamine 2,3-dioxygenase in normal and malaria-infected tissue. Redox 1.4 Report, 2000, 5, 112-115. Functional characterization and mechanism of action of recombinant human kynurenine 112 0.2 64 3-hydroxylase. FEBS Journal, 2000, 267, 1092-1099. Selective metabolism of kynurenine in the spleen in the absence of indoleamine 2,3-dioxygenase induction. Immunology Letters, 2000, 71, 67-72. Tryptophan degradation and immune activation in Alzheimer's disease. Journal of Neural Transmission, 114 1.4 250 2000, 107, 343-353. Kynurenic acid metabolism in the brain of HIV-1 infected patients. Journal of Neural Transmission, 1.4 37 2000, 107, 1127-1138. Anticonvulsant effects of the 3-hydroxyanthranilic acid dioxygenase inhibitor NCR-631. Amino Acids, 116 1.2 8 2000, 19, 325-334. Mechanism of increases in<scp>l</scp>-kynurenine and quinolinic acid in renal insufficiency. 1.3 146 American Journal of Physiology - Renal Physiology, 2000, 279, F565-F572. Interferon gama induced Tryptophan Degradation Neuropsychiatric and Immunological Consequences. 118 0.7 111 Current Drug Metabolism, 2000, 1, 193-204. Mind Glue. Archives of General Psychiatry, 2000, 57, 90. 13.8 108 An Indoleamine 2,3-Dioxygenase-Negative Mutant Is Defective in Stat1 DNA Binding: Differential 120 0.5 11 Response to IFN-Î³ and IFŇ-α. Journal of Interferon and Cytokine Research, 2000, 2Ŏ, 623-632. Neuro-Immune Interactions in Neurologic and Psychiatric Disorders. Research and Perspectives in 0.4 Neurosciences, 2000, , . Understanding Cytokines Part I: Physiology and Mechanism of Action. Biological Research for 122 1.0 65 Nursing, 2000, 2, 30-40. Enhanced Tryptophan Degradation in Systemic Lupus Erythematosus. Immunobiology, 2000, 201, 621-630. 0.8 It is hazardous to treat HIV patients with interferon- $\hat{1}_{\pm}$. Medical Hypotheses, 2000, 54, 131-136. 124 0.8 5 Melatonin reduces oxidative neurotoxicity due to quinolinic acid:. Neuropharmacology, 2000, 39, 507-514. IFN-Î²1bInduces Kynurenine Pathway Metabolism in Human Macrophages: Potential Implications for 126 0.5 79 Multiple Sclerosis Treatment. Journal of Interferon and Cytokine Research, 2001, 21, 1097-1101. Ouinolinic acid â€" Iron(II) complexes: Slow autoxidation, but enhanced hydroxyl radical production in 1.5 the Fenton reaction. Free Radical Research, 2001, 34, 445-459.

		CITATION REP	ORT	
#	Article		IF	CITATIONS
128	Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in cord of rats with experimental allergic encephalomyelitis. Neuroscience, 2001, 102, 687-69	:he spinal 95.	1.1	98
129	Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Progress in Neurobiology, 2001, 64, 185-218.	n	2.8	282
130	Endogenous neurotoxins from tryptophan. Toxicon, 2001, 39, 61-73.		0.8	127
131	Apoptosis in HIV disease pathogenesis. Advances in Cell Aging and Gerontology, 2001, , 10)1-136.	0.1	1
132	Decreased Expression of MAP-2 and GAD in the Brain of Cats Infected with Feline Immunoc Virus Tohoku Journal of Experimental Medicine, 2001, 195, 141-151.	leficiency	0.5	7
133	Localizing value of α-methyl- <scp>L</scp> -tryptophan PET in intractable epilepsy of neoc Neurology, 2001, 57, 1629-1636.	ortical origin.	1.5	100
134	Neopterin Production and Tryptophan Degradation in Patients with Neurodegenerative Dis between Immune Activation and Neuropsychiatric Symptoms. , 2001, 20, 30-40.	eases: Link		0
135	The role of kynurenines in the production of neuronal death, and the neuroprotective effect purines. Journal of Alzheimer's Disease, 2001, 3, 355-366.	t of	1.2	26
136	Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochemistry, 2001, 78, 842-853.	ournal of	2.1	438
137	Study of the brain serotonergic system with labeled α-methyl-l-tryptophan. Journal of Neur 2001, 78, 1185-1200.	ochemistry,	2.1	102
138	Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macroph Journal of Neuroimmunology, 2001, 117, 97-107.	ages.	1.1	136
139	Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived n Journal of Neuroimmunology, 2001, 120, 190-198.	acrophages.	1.1	114
140	Oligodendrocyte killing by quinolinic acid in vitro. Brain Research, 2001, 896, 157-160.		1.1	41
141	Kynurenine production and catabolism in fetal sheep with embolized or nonembolized plac American Journal of Obstetrics and Gynecology, 2001, 185, 988-995.	entas.	0.7	14
142	Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebr volume loss in HIV infection. Brain, 2001, 124, 1033-1042.	al	3.7	102
143	Simian immunodeficiency virus model of HIV induced central nervous system dysfunction. Virus Research, 2001, 56, 435-468.	Advances in	0.9	45
144	Neonatal Asphyxia in Rats: Acute Effects on Cerebral Kynurenine Metabolism. Pediatric Res 50, 231-235.	earch, 2001,	1.1	25
145	Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox R 7, 199-206.	eport, 2002,	1.4	167

#	Article	IF	CITATIONS
146	Expression of Indoleamine 2,3-Dioxygenase, Tryptophan Degradation, and Kynurenine Formation during In Vivo Infection with Toxoplasma gondii : Induction by Endogenous Gamma Interferon and Requirement of Interferon Regulatory Factor 1. Infection and Immunity, 2002, 70, 859-868.	1.0	184
147	The Clinical Significance of Cerebrospinal Fluid Levels of Kynurenine Pathway Metabolites and Lactate in Severe Malaria. Journal of Infectious Diseases, 2002, 185, 650-656.	1.9	66
148	Regulation of Indoleamine 2,3-Dioxygenase Expression in Simian Immunodeficiency Virus-Infected Monkey Brains. Journal of Virology, 2002, 76, 12233-12241.	1.5	42
149	The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. International Journal of Neuropsychopharmacology, 2002, 5, 375-388.	1.0	276
150	l-Tryptophan-l-Kynurenine Pathway Metabolism Accelerated by Toxoplasmagondii Infection Is Abolished in Gamma Interferon-Gene-Deficient Mice: Cross-Regulation between Inducible Nitric Oxide Synthase and Indoleamine-2,3-Dioxygenase. Infection and Immunity, 2002, 70, 779-786.	1.0	136
151	Novel Protein Modification by Kynurenine in Human Lenses. Journal of Biological Chemistry, 2002, 277, 4867-4873.	1.6	121
152	Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sciences, 2002, 71, 1837-1848.	2.0	177
153	Effective Antiretroviral Therapy Reduces Degradation of Tryptophan in Patients with HIV-1 Infection. Clinical Immunology, 2002, 104, 242-247.	1.4	84
154	Immunologic Alterations in Schizophrenia: Neopterin, L-Kynurenine, Tryptophan and T-Cell Subsets in the Acute Stage of Illness. Pteridines, 2002, 13, 9-14.	0.5	5
155	Cloning of human 3-hydroxyanthranilic acid dioxygenase in Escherichia coli: characterisation of the purified enzyme and its in vitro inhibition by Zn2+. BBA - Proteins and Proteomics, 2002, 1596, 283-292.	2.1	16
156	Concurrent Quantification of Quinolinic, Picolinic, and Nicotinic Acids Using Electron-Capture Negative-Ion Gas Chromatography–Mass Spectrometry. Analytical Biochemistry, 2002, 301, 21-26.	1.1	91
157	Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. Journal of Neural Transmission, 2002, 109, 181-189.	1.4	143
158	Mechanisms of interferon-alpha-induced depressive symptoms. Acta Neuropsychiatrica, 2002, 14, 103-105.	1.0	6
159	Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the l-kynurenine and quinolinic acid pools in brain. Journal of Neurochemistry, 2002, 82, 258-268.	2.1	101
160	Cerebrospinal Fluid Nitrite/Nitrate Levels in Neurologic Diseases. Journal of Neurochemistry, 1994, 63, 1178-1180.	2.1	99
161	Neurotoxin Quinolinic Acid Is Selectively Elevated in Spinal Cords of Rats with Experimental Allergic Encephalomyelitis. Journal of Neurochemistry, 1995, 64, 1192-1196.	2.1	62
162	Regulation of the Kynurenine Metabolic Pathway by Interferonâ€Î³ in Murine Cloned Macrophages and Microglial Cells. Journal of Neurochemistry, 1996, 66, 996-1004.	2.1	158
163	Quinolinic Acid In Vivo Synthesis Rates, Extracellular Concentrations, and Intercompartmental Distributions in Normal and Immuneâ€Activated Brain as Determined by Multipleâ€Isotope Microdialysis. Journal of Neurochemistry, 1998, 70, 281-291.	2.1	48

#	Article	IF	CITATIONS
164	Depletion of Systemic Macrophages by Liposome-Encapsulated Clodronate Attenuates Increases in Brain Quinolinic Acid During CNS-Localized and Systemic Immune Activation. Journal of Neurochemistry, 2002, 73, 770-779.	2.1	15
165	Is Tourette's syndrome an autoimmune disease?. Molecular Psychiatry, 2002, 7, 437-445.	4.1	62
166	Endogenous kynurenines as targets for drug discovery and development. Nature Reviews Drug Discovery, 2002, 1, 609-620.	21.5	646
167	Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists. British Journal of Pharmacology, 2002, 135, 1435-1442.	2.7	57
168	The vitamin-E analog trolox and the NMDA antagonist MK-801 protect pyramidal neurons in hippocampal slice cultures from IL-1β-induced neurodegeneration. Neurotoxicity Research, 2003, 5, 433-441.	1.3	22
170	Copper blocks quinolinic acid neurotoxicity in rats: contribution of antioxidant systems. Free Radical Biology and Medicine, 2003, 35, 418-427.	1.3	40
171	Inhibition of indoleamine 2,3-dioxygenase activity in IFN-γ stimulated astroglioma cells decreases intracellular NAD levels. Biochemical Pharmacology, 2003, 66, 1033-1036.	2.0	46
172	Reconstructing eukaryotic NAD metabolism. BioEssays, 2003, 25, 683-690.	1.2	250
173	α-[11C]-Methyl-l-tryptophan PET identifies the epileptogenic tuber and correlates with interictal spike frequency. Epilepsy Research, 2003, 52, 203-213.	0.8	79
174	Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 2003, 107, 412-418.	1.0	61
175	Immune activation and degradation of tryptophan in coronary heart disease. European Journal of Clinical Investigation, 2003, 33, 550-554.	1.7	156
176	Tryptophan Metabolites and Brain Disorders. Clinical Chemistry and Laboratory Medicine, 2003, 41, 852-9.	1.4	139
177	Metabolites of the Kynurenine Pathway of Tryptophan Metabolism in the Cerebrospinal Fluid of Malawian Children with Malaria. Journal of Infectious Diseases, 2003, 188, 844-849.	1.9	97
178	Developmental Psychoneuroimmunology: The Role of Cytokine Network Activation in the Epigenesis of Developmental Psychopathology. , 2003, , 293-323.		3
179	Porcine Choroid Plexus Epithelial Cells Induce Streptococcus suis Bacteriostasis In Vitro. Infection and Immunity, 2004, 72, 3084-3087.	1.0	19
180	St. John's wort (Hypericum perforatum) counteracts cytokine-induced tryptophan catabolism in vitro. Biological Chemistry, 2004, 385, 1197-1202.	1.2	25
181	CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain, 2004, 127, 1047-1060.	3.7	50
182	Assessment of the Macrophage Marker Quinolinic Acid in Cerebrospinal Fluid after Pediatric Traumatic Brain Injury: Insight into the Timing and Severity of Injury in Child Abuse. Journal of Neurotrauma, 2004, 21, 1123-1130.	1.7	28

#	Article	IF	CITATIONS
183	Increased expression of indoleamine 2,3-dioxygenase in murine malaria infection is predominantly localised to the vascular endothelium. International Journal for Parasitology, 2004, 34, 1309-1319.	1.3	76
184	The Microcirculation in Severe Malaria. Microcirculation, 2004, 11, 559-576.	1.0	52
185	Pharmacological Manipulation of Brain Kynurenine Metabolism. Annals of the New York Academy of Sciences, 2004, 1035, 335-349.	1.8	18
186	Enzymology of NAD+ homeostasis in man. Cellular and Molecular Life Sciences, 2004, 61, 19-34.	2.4	259
187	Antibiotic-mediated release of tumour necrosis factor alpha and norharman in patients with hospital-acquired pneumonia and septic encephalopathy. Intensive Care Medicine, 2004, 30, 1544-51.	3.9	25
188	Protective effects of the antioxidant selenium on quinolinic acid-induced neurotoxicity in rats: in vitro and in vivo studies. Journal of Neurochemistry, 2004, 86, 479-488.	2.1	95
189	Cytokines: abnormalities in major depression and implications for pharmacological treatment. Human Psychopharmacology, 2004, 19, 397-403.	0.7	271
190	Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiology of Disease, 2004, 17, 455-461.	2.1	221
191	Evaluation of three quinoline-carboxamide derivatives as potential radioligands for the in vivo pet imaging of neurodegeneration. Neurochemistry International, 2004, 44, 433-440.	1.9	55
192	Tryptophan metabolism and oxidative stress in patients with Huntington's disease. Journal of Neurochemistry, 2005, 93, 611-623.	2.1	271
193	Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus. Neuropathology and Applied Neurobiology, 2005, 31, 395-404.	1.8	272
194	Involvement of quinolinic acid in aids dementia complex. Neurotoxicity Research, 2005, 7, 103-123.	1.3	117
195	Krebs Cycle Intermediates Modulate Thiobarbituric Acid Reactive Species (TBARS) Production in Rat Brain In Vitro. Neurochemical Research, 2005, 30, 225-235.	1.6	287
196	Age-Related Increase of Kynurenic Acid in Human Cerebrospinal Fluid – IgG and β ₂ -Microglobulin Changes. NeuroSignals, 2005, 14, 126-135.	0.5	77
197	Implications for the Kynurenine Pathway and Quinolinic Acid in Amyotrophic Lateral Sclerosis. Neurodegenerative Diseases, 2005, 2, 166-176.	0.8	88
198	Deprenyl enhances the striatal neuronal damage produced by quinolinic acid. Molecular Brain Research, 2005, 141, 48-57.	2.5	2
199	Neuronal localization of indoleamine 2,3-dioxygenase in mice. Neuroscience Letters, 2005, 387, 95-99.	1.0	27
200	Cerebrospinal Fluid and Serum Markers of Inflammation in Autism. Pediatric Neurology, 2005, 33, 195-201.	1.0	268

#	Article	IF	CITATIONS
201	Cytokines and major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 201-217.	2.5	1,010
202	Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. Journal of Neuroinflammation, 2005, 2, 16.	3.1	114
203	Oxidative Damage in Huntington's Disease Pathogenesis. Antioxidants and Redox Signaling, 2006, 8, 2061-2073.	2.5	275
204	Neuroimmune–endocrine crosstalk in schizophrenia and mood disorders. Expert Review of Neurotherapeutics, 2006, 6, 1017-1038.	1.4	59
205	Monitoring tryptophan metabolism in chronic immune activation. Clinica Chimica Acta, 2006, 364, 82-90.	0.5	489
206	The Signal Transducer and Activator of Transcription 1α and Interferon Regulatory Factor 1 Are Not Essential for the Induction of Indoleamine 2,3-Dioxygenase by Lipopolysaccharide: Involvement of p38 Mitogen-Activated Protein Kinase and Nuclear Factor-I®B Pathways, and Synergistic Effect of Several Proinflammatory Cytokines, Journal of Biochemistry, 2006, 139, 655-662.	0.9	193
207	Time course of oxidative events in the hippocampus following intracerebroventricular infusion of quinolinic acid in mice. Neuroscience Research, 2006, 55, 397-402.	1.0	29
208	Serial Analysis of Tryptophan Degradation and Neopterin Formation in an otherwise Healthy Individual before and during an Infectious Episode. Pteridines, 2006, 17, 25-30.	0.5	1
209	Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats. Journal of Neurochemistry, 2006, 99, 1531-1542.	2.1	55
210	Tryptophan metabolism and oxidative stress in patients with chronic brain injury. European Journal of Neurology, 2006, 13, 30-42.	1.7	107
211	Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro. Rheumatology International, 2006, 26, 422-426.	1.5	39
212	Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiology of Disease, 2006, 23, 190-197.	2.1	137
213	Study of tryptophan metabolism via serotonin in cerebrospinal fluid of patients with noncommunicating hydrocephalus using a new endoscopic technique. Journal of Neuroscience Research, 2006, 84, 683-691.	1.3	9
214	Antitumoral Activity of Interferon-γ Involved in Impaired Immune Function in Cancer Patients. Current Drug Metabolism, 2006, 7, 599-612.	0.7	83
215	Sleep disorders are long-term sequelae of both bacterial and viral meningitis. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 554-558.	0.9	29
216	4-Chloro-3-Hydroxyanthranilate Reduces Local Quinolinic Acid Synthesis, Improves Functional Recovery, and Preserves White Matter after Spinal Cord Injury. Journal of Neurotrauma, 2006, 23, 866-881.	1.7	20
217	Kynurenic Acid as a Ligand for Orphan G Protein-coupled Receptor GPR35. Journal of Biological Chemistry, 2006, 281, 22021-22028.	1.6	530
218	Implications of IFN-γ-Mediated Tryptophan Catabolism on Solid Organ Transplantation. Current Drug Metabolism, 2007, 8, 273-282.	0.7	38

#	Article	IF	CITATIONS
219	Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 85, 261-300.	1.0	24
220	Role of the blood-brain barrier and blood-CSF barrier in the pathogenesis of bacterial meningitis. , 2007, , 199-237.		0
221	Recurrent Headache as the Main Symptom of Acquired Cerebral Toxoplasmosis in Nonhuman Immunodeficiency Virus-infected Subjects With no Lymphadenopathy. American Journal of Therapeutics, 2007, 14, 63-105.	0.5	33
222	Acute psychotic symptoms in HIV-1 infected patients are associated with increased levels of kynurenic acid in cerebrospinal fluid. Brain, Behavior, and Immunity, 2007, 21, 86-91.	2.0	46
223	Mechanisms by which acyclovir reduces the oxidative neurotoxicity and biosynthesis of quinolinic acid. Life Sciences, 2007, 80, 918-925.	2.0	17
224	Non-steroidal anti-inflammatory agents, tolmetin and sulindac attenuate quinolinic acid (QA)-induced oxidative stress in primary hippocampal neurons and reduce QA-induced spatial reference memory deficits in male Wistar rats. Life Sciences, 2007, 80, 1431-1438.	2.0	12
225	In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain. Neurochemistry International, 2007, 50, 83-94.	1.9	77
226	Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochemistry International, 2007, 50, 308-313.	1.9	112
227	In vitro effect of quinolinic acid on energy metabolism in brain of young rats. Neuroscience Research, 2007, 57, 277-288.	1.0	24
228	Evidence for a synergistic action of glutaric and 3â€hydroxyglutaric acids disturbing rat brain energy metabolism. International Journal of Developmental Neuroscience, 2007, 25, 391-398.	0.7	36
229	Role of paroxetine in interferon-α-induced immune and behavioural changes in male Wistar rats. Journal of Psychopharmacology, 2007, 21, 843-850.	2.0	34
230	Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. Journal of the Neurological Sciences, 2007, 257, 221-239.	0.3	381
231	Pharmacology of the kynurenine pathway. International Congress Series, 2007, 1304, 298-304.	0.2	3
232	Kynurenic acid actions in brain and periphery. International Congress Series, 2007, 1304, 305-313.	0.2	22
233	Assessment of the kynurenine pathway in humans: I. Normal plasma values, ethnic differences and their clinical implications. International Congress Series, 2007, 1304, 335-343.	0.2	6
234	Neuroimmune Correlates of Sleep in Depression: Role of Cytokines. , 2007, , 295-319.		1
235	Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia, 2007, 55, 78-92.	2.5	123
236	IFNâ€Î³â€induced IDO and WRS expression in microglia is differentially regulated by ILâ€4. Glia, 2007, 55, 1385-1396.	2.5	51

#	Article	IF	CITATIONS
237	Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Molecular Psychiatry, 2007, 12, 522-543.	4.1	313
238	Altered kynurenine metabolism correlates with infarct volume in stroke. European Journal of Neuroscience, 2007, 26, 2211-2221.	1.2	135
239	Kynurenine pathway in major depression: Evidence of impaired neuroprotection. Journal of Affective Disorders, 2007, 98, 143-151.	2.0	470
240	Decreased protein nitration in macrophages that overexpress indoleamine 2, 3-dioxygenase. Cellular and Molecular Biology Letters, 2007, 12, 82-102.	2.7	12
241	The involvement of astrocytes and kynurenine pathway in Alzheimer's disease. Neurotoxicity Research, 2007, 12, 247-262.	1.3	46
242	Tryptophan, adenosine, neurodegeneration and neuroprotection. Metabolic Brain Disease, 2007, 22, 337-352.	1.4	52
243	Kynurenines Impair Energy Metabolism in Rat Cerebral Cortex. Cellular and Molecular Neurobiology, 2007, 27, 147-160.	1.7	29
244	A psychoneuroimmunological perspective to Emil Kraepelins dichotomy. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 97-106.	1.8	111
245	Induction of the kynurenine pathway by neurotropic influenza a virus infection. Journal of Neuroscience Research, 2008, 86, 3674-3683.	1.3	40
246	Neuronâ€microglia crosstalk upâ€regulates neuronal FGFâ€2 expression which mediates neuroprotection against excitotoxicity via JNK1/2. Journal of Neurochemistry, 2008, 107, 73-85.	2.1	40
247	Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferonâ€i±: Course and relationship with psychiatric status. Psychiatry and Clinical Neurosciences, 2008, 62, 597-602.	1.0	22
248	Abnormal sleep–wake cycles in patients with tuberculous meningitis: A case-control study. Journal of the Neurological Sciences, 2008, 269, 126-132.	0.3	8
249	Theoretical Studies of the Quinolinic Acid to Nicotinic Acid Mononucleotide Transformation. Journal of Organic Chemistry, 2008, 73, 9314-9319.	1.7	2
250	Cerebrospinal Fluid. , 2008, , 769-819.		25
251	PREVENTION BY MAGNESIUM OF EXOTOTOXIC NEURONAL DEATH IN THE DEVELOPING BRAIN: AN ANIMAL MODEL FOR CLINICAL INTERVENTION STUDIES. Developmental Medicine and Child Neurology, 1995, 37, 473-484.	1.1	147
252	Polyfunctional Recognition of Pyridinedicarboxylate Anions with Macrocyclic Polyamine Receptors Containing Heteroaromatic Groups. Journal of Organic Chemistry, 2008, 73, 8286-8295.	1.7	13
253	<scp>L</scp> -kynurenine: metabolism and mechanism of neuroprotection. Future Neurology, 2008, 3, 169-188.	0.9	30
254	Neurometabolic Effects of ACTH on Free Amino Compounds in Opsoclonus-myoclonus Syndrome. Neuropediatrics, 2008, 39, 164-171.	0.3	3

#	Article	IF	CITATIONS
255	COX-2 Inhibition in Schizophrenia and Major Depression. Current Pharmaceutical Design, 2008, 14, 1452-1465.	0.9	94
256	Effects of Kynurenine Pathway Metabolites on Intracellular NAD+ Synthesis and Cell Death in Human Primary Astrocytes and Neurons. International Journal of Tryptophan Research, 2009, 2, IJTR.S2318.	1.0	69
257	The Physiological Action of Picolinic Acid in the Human Brain. International Journal of Tryptophan Research, 2009, 2, IJTR.S2469.	1.0	142
258	Kynurenic Acid Triggers Firm Arrest of Leukocytes to Vascular Endothelium under Flow Conditions. Journal of Biological Chemistry, 2009, 284, 19189-19195.	1.6	124
259	Long-term exposure to nicotine markedly reduces kynurenic acid in rat brain — In vitro and ex vivo evidence. Toxicology and Applied Pharmacology, 2009, 240, 174-179.	1.3	9
260	The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metabolic Brain Disease, 2009, 24, 27-53.	1.4	775
261	Plasma tryptophan and tyrosine levels are independent risk factors for delirium in critically ill patients. Intensive Care Medicine, 2009, 35, 1886-1892.	3.9	83
262	Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-α and ribavirin treatment. Molecular Psychiatry, 2009, 14, 1095-1104.	4.1	214
263	Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis. Journal of Neurochemistry, 2009, 108, 158-164.	2.1	42
264	Age and circadian influences on picolinic acid concentrations in human cerebrospinal fluid. Journal of Neurochemistry, 2009, 108, 1220-1225.	2.1	37
265	Proinflammatory cytokine interferonâ€Î³ increases induction of indoleamine 2,3â€dioxygenase in monocytic cells primed with amyloid β peptide 1–42: implications for the pathogenesis of Alzheimer's disease. Journal of Neurochemistry, 2009, 110, 791-800.	2.1	53
266	Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease. Behavioural Brain Research, 2009, 199, 210-217.	1.2	37
267	The role of kynurenines in disorders of the central nervous system: Possibilities for neuroprotection. Journal of the Neurological Sciences, 2009, 283, 21-27.	0.3	109
268	Pharmacological Manipulation of Kynurenic Acid. CNS Drugs, 2009, 23, 91-101.	2.7	138
269	Kynurenine Pathway Metabolites in Humans: Disease and Healthy States. International Journal of Tryptophan Research, 2009, 2, IJTR.S2097.	1.0	501
270	Depression has a Strong Relationship to Alterations in the Immune, Endocrine and Neural System. Current Psychiatry Reviews, 2009, 5, 287-297.	0.9	16
271	Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1â^'/â^' mice. International Journal of Neuropsychopharmacology, 2010, 13, 475.	1.0	46
272	Genomics and Enzymology of NAD Biosynthesis. , 2010, , 213-257.		46

#	Article	IF	CITATIONS
273	3-Nitropropionic Acid as a Tool to Study the Mechanisms Involved in Huntington's Disease: Past, Present and Future. Molecules, 2010, 15, 878-916.	1.7	163
274	Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder. International Journal of Tryptophan Research, 2010, 3, IJTR.S4321.	1.0	50
275	Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2,3-dioxygenase and serotonin in immature dendritic cells: Implications for neuroAIDS. Journal of NeuroVirology, 2010, 16, 255-263.	1.0	28
276	Oren-gedoku-to and its Constituents with Therapeutic Potential in Alzheimer's Disease Inhibit Indoleamine 2, 3-Dioxygenase Activity In Vitro. Journal of Alzheimer's Disease, 2010, 22, 257-266.	1.2	78
277	Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cellular and Molecular Life Sciences, 2010, 67, 353-368.	2.4	194
278	Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2. Amino Acids, 2010, 39, 565-578.	1.2	61
279	Kynurenines, neurodegeneration and Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2010, 14, 2045-2054.	1.6	57
280	Kynurenic acid in blood and bone marrow plasma of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients. Leukemia Research, 2010, 34, 38-45.	0.4	6
281	CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-α: relationship to CNS immune responses and depression. Molecular Psychiatry, 2010, 15, 393-403.	4.1	546
282	Autoimmune processes after long-term low-level exposure to electromagnetic fields part 4. Oxidative intracellular stress response to the long-term rat exposure to nonthermal RF EMF. Biophysics (Russian Federation), 2010, 55, 1054-1058.	0.2	2
283	Pain Patients. , 2010, , 211-236.		2
284	The Secret Life of NAD+: An Old Metabolite Controlling New Metabolic Signaling Pathways. Endocrine Reviews, 2010, 31, 194-223.	8.9	731
285	Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. Journal of Psychiatry and Neuroscience, 2010, 35, 195-199.	1.4	87
286	Kynurenine and its metabolites in Alzheimer's disease patients. Advances in Medical Sciences, 2010, 55, 204-211.	0.9	215
287	Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats. NeuroToxicology, 2010, 31, 195-203.	1.4	25
288	Neopterin, a prognostic marker in human malignancies. Cancer Letters, 2010, 287, 13-22.	3.2	138
289	Increased serum free tryptophan in patients with diarrhea-predominant irritable bowel syndrome. Nutrition Research, 2010, 30, 678-688.	1.3	35
290	The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Review of Neurotherapeutics, 2010, 10, 59-76.	1.4	245

		CITATION R	EPORT	
#	Article		IF	CITATIONS
291	Pathobiological targets of depression. Expert Opinion on Therapeutic Targets, 2011, 1	5, 379-400.	1.5	58
292	Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration. Cell 863-874.	, 2011, 145,	13.5	435
293	Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic Huntington's disease-like alterations in rats. Life Sciences, 2011, 88, 784-791.	: acid induced	2.0	25
294	Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut, 2011, 60, 1	671-1677.	6.1	109
295	Effect of some naturally occurring iron ion chelators on the formation of radicals in the mixtures of rat liver microsomes with ADP, Fe3+ and NADPH. Journal of Clinical Bioche Nutrition, 2011, 49, 207-215.	? reaction mistry and	0.6	15
296	Kynurenine metabolism predicts cognitive function in patients following cardiac bypas surgery. Journal of Neurochemistry, 2011, 119, 136-152.	s and thoracic	2.1	45
297	Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged fema FEBS Journal, 2011, 278, 4425-4434.	ale Wistar rats.	2.2	93
298	Endogenous neuroprotection in chronic neurodegenerative disorders: with particular r kynurenines. Journal of Cellular and Molecular Medicine, 2011, 15, 701-717.	egard to the	1.6	50
299	Inflammation-associated depression: From serotonin to kynurenine. Psychoneuroendo 36, 426-436.	crinology, 2011,	1.3	626
300	Structure–activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazole 2,3-dioxygenase (IDO) inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 5	es as indoleamine 5680-5687.	2.6	63
301	Targeting the kynurenine pathway as a potential strategy to prevent and treat Alzheim Medical Hypotheses, 2011, 77, 383-385.	ıer's disease.	0.8	19
302	Flipping the switches: CD40 and CD45 modulation of microglial activation states in HI dementia (HAD). Molecular Neurodegeneration, 2011, 6, 3.	V associated	4.4	26
303	Duodenal mass in a patient with weight loss and liver dysfunction. Gut, 2011, 60, 1659	9-1660.	6.1	6
304	Stochastic Resonance Activity Influences Serum Tryptophan Metabolism in Healthy Hu International Journal of Tryptophan Research, 2011, 4, IJTR.S7986.	man Subjects.	1.0	8
305	Vagus Nerve Stimulation in Refractory Epilepsy: Effects on Pro- and Anti-Inflammatory Peripheral Blood. NeuroImmunoModulation, 2011, 18, 52-56.	Cytokines in	0.9	73
306	Kynurenic Acid Metabolism in Various Types of Brain Pathology in HIV-1 Infected Patier Journal of Tryptophan Research, 2012, 5, IJTR.S10627.	nts. International	1.0	14
307	Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interfero depression in patients with chronic hepatitis C. Molecular Psychiatry, 2012, 17, 781-78	n-α-induced 39.	4.1	74
308	Somatic Drugs for Psychiatric Diseases: Aspirin or Simvastatin for Depression?. Current Neuropharmacology, 2012, 10, 139-158.		1.4	25

#	Article	IF	CITATIONS
309	The association of the kynurenine pathway of tryptophan metabolism with acute brain dysfunction during critical illness*. Critical Care Medicine, 2012, 40, 835-841.	0.4	52
311	Gas chromatography/tandem mass spectrometry detection of extracellular kynurenine and related metabolites in normal and lesioned rat brain. Analytical Biochemistry, 2012, 421, 573-581.	1.1	44
312	Post-Myocardial Infarction Depression. , 0, , .		1
313	Immune activation and neuropsychiatric symptoms in human immunodeficiency virus type 1 infection. Neurobehavioral HIV Medicine, 2012, , 1.	2.0	1
314	The Kynurenine Pathway. , 2012, , .		5
315	Kynurenines in the mammalian brain: when physiology meets pathology. Nature Reviews Neuroscience, 2012, 13, 465-477.	4.9	1,129
316	Elevated cerebrospinal fluid kynurenic acid levels in patients with tickâ€borne encephalitis. Journal of Internal Medicine, 2012, 272, 394-401.	2.7	28
317	Kynurenines: from the perspective of major psychiatric disorders. FEBS Journal, 2012, 279, 1375-1385.	2.2	193
318	Plasma adiponectin elevation in elderly individuals with subsyndromal depression. Psychoneuroendocrinology, 2012, 37, 948-955.	1.3	40
319	Creatine and pyruvate prevent behavioral and oxidative stress alterations caused by hypertryptophanemia in rats. Molecular and Cellular Biochemistry, 2012, 362, 225-232.	1.4	10
320	Involvement of kynurenines in Huntington's disease and stroke-induced brain damage. Journal of Neural Transmission, 2012, 119, 261-274.	1.4	51
321	The role of the kynurenine metabolism in major depression. Journal of Neural Transmission, 2012, 119, 245-251.	1.4	91
322	The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications. Journal of Neural Transmission, 2012, 119, 225-234.	1.4	24
323	The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease. Journal of Molecular Medicine, 2013, 91, 705-713.	1.7	42
324	The emerging roles of AhR in physiology and immunity. Biochemical Pharmacology, 2013, 86, 561-570.	2.0	164
325	Ageâ€dependent alterations of the kynurenine pathway in the <scp>YAC</scp> 128 mouse model of Huntington disease. Journal of Neurochemistry, 2013, 127, 852-867.	2.1	27
326	Neurotranmission systems as targets for toxicants: a review. Cell Biology and Toxicology, 2013, 29, 381-396.	2.4	40
327	Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice. Journal of Medicinal Chemistry, 2013, 56, 8321-8331.	2.9	154

#	Article	IF	CITATIONS
328	Inflammation in Suicidality: Implications for Novel Treatment Options. Modern Problems of Pharmacopsychiatry, 2013, 28, 188-202.	2.5	8
329	Microglia/Macrophage-Derived Inflammatory Mediators Galectin-3 and Quinolinic Acid are Elevated in Cerebrospinal Fluid from Newborn Infants After Birth Asphyxia. Translational Stroke Research, 2013, 4, 228-235.	2.3	41
330	Kynurenines in the CNS: recent advances and new questions. Nature Reviews Drug Discovery, 2013, 12, 64-82.	21.5	480
331	Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology, 2013, 38, 743-752.	2.8	287
332	Kynurenic Acid in Plasma and Endometrium in Bitches with Pyometra. Inflammation, 2013, 36, 131-135.	1.7	5
333	Activation of kynurenine pathway in exÂvivo fibroblasts from patients with bipolar disorder or schizophrenia: Cytokine challenge increases production of 3-hydroxykynurenine. Journal of Psychiatric Research, 2013, 47, 1815-1823.	1.5	61
334	Kynurenic Acid in Synovial Fluid and Serum of Patients with Rheumatoid Arthritis, Spondyloarthropathy, and Osteoarthritis. Journal of Rheumatology, 2013, 40, 903-909.	1.0	15
335	Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications. Neuroscience, 2013, 246, 199-229.	1.1	817
336	Kynurenines and other novel therapeutic strategies in the treatment of dementia. Therapeutic Advances in Neurological Disorders, 2013, 6, 386-397.	1.5	19
337	An Investigation of the Antidepressant Action of Xiaoyaosan in Rats Using Ultra performance Liquid Chromatography–Mass Spectrometry Combined with Metabonomics. Phytotherapy Research, 2013, 27, 1074-1085.	2.8	31
338	Antiviral activity of interferon-Î ³ involved in impaired immune function in infectious diseases. Pteridines, 2013, 24, 149-164.	0.5	4
339	Acute tryptophan depletion in humans: a review of theoretical, practical and ethical aspects. Journal of Psychiatry and Neuroscience, 2013, 38, 294-305.	1.4	89
340	Species and Cell Types Difference in Tryptophan Metabolism. International Journal of Tryptophan Research, 2013, 6s1, IJTR.S11558.	1.0	29
341	Genes and functional <scp>GI</scp> disorders: from casual to causal relationship. Neurogastroenterology and Motility, 2013, 25, 638-649.	1.6	27
343	Metabolomics Study of Protective Effects of Shexiang Baoxin Pill and its Bioactive Constitutes Combination in Treating the Early Period of Acute Myocardial Infarction in Rats. Alternative & Integrative Medicine, 2013, 02, .	0.1	0
344	Immunomodulatory properties of cacao extracts – potential consequences for medical applications. Frontiers in Pharmacology, 2013, 4, 154.	1.6	7
346	Differential effects of sertraline in a predator exposure animal model of post-traumatic stress disorder. Frontiers in Behavioral Neuroscience, 2014, 8, 256.	1.0	41
347	Kynurenines with Neuroactive and Redox Properties: Relevance to Aging and Brain Diseases. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-22.	1.9	95

	CITATION	CITATION REPORT	
#	Article	IF	CITATIONS
348	The kynurenine pathway is involved in bacterial meningitis. Journal of Neuroinflammation, 2014, 11, 169.	3.1	34
349	Early Activation of the Kynurenine Pathway Predicts Early Death and Longâ€ŧerm Outcome in Patients Resuscitated From Outâ€ofâ€Hospital Cardiac Arrest. Journal of the American Heart Association, 2014, 3, .	1.6	34
350	Immune changes and neurotransmitters: Possible interactions in depression?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 268-276.	2.5	103
351	Adaptive Immunity and Genetics of the Host Immune Response. , 2014, , 819-994.		4
352	The potential role of kynurenines in Alzheimer's disease: pathomechanism and therapeutic possibilities by influencing the glutamate receptors. Journal of Neural Transmission, 2014, 121, 881-889.	1.4	18
353	Network beyond IDO in psychiatric disorders: Revisiting neurodegeneration hypothesis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 304-313.	2.5	184
354	Depression as a Risk Factor for Cancer: From Pathophysiological Advances to Treatment Implications. Annual Review of Medicine, 2014, 65, 203-221.	5.0	88
355	Behavioral disturbances in adult mice following neonatal virus infection or kynurenine treatment – Role of brain kynurenic acid. Brain, Behavior, and Immunity, 2014, 36, 80-89.	2.0	37
356	Development of a liquid chromatography–mass spectrometry method for the determination of the neurotoxic quinolinic acid in human serum. Clinica Chimica Acta, 2014, 436, 268-272.	0.5	26
357	Clia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application. Translational Psychiatry, 2014, 4, e350-e350.	2.4	80
358	Inflammation: a mechanism of depression?. Neuroscience Bulletin, 2014, 30, 515-523.	1.5	75
359	Salivary cytokines in healthy adolescent girls: Intercorrelations, stability, and associations with serum cytokines, age, and pubertal stage. Developmental Psychobiology, 2014, 56, 797-811.	0.9	82
360	The kynurenine pathway contributes to long-term neuropsychological changes in experimental pneumococcal meningitis. Behavioural Brain Research, 2014, 270, 179-195.	1.2	10
361	The Fe-heme structure of met-indoleamine 2,3-dioxygenase-2 determined by X-ray absorption fine structure. Biochemical and Biophysical Research Communications, 2014, 450, 25-29.	1.0	4
362	Kynurenic Acid Levels in Cerebrospinal Fluid from Patients with Alzheimer's Disease or Dementia with Lewy Bodies. International Journal of Tryptophan Research, 2014, 7, IJTR.S13958.	1.0	36
363	The role of inflammation in suicidal behaviour. Acta Psychiatrica Scandinavica, 2015, 132, 192-203.	2.2	137
364	Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans. Journal of Neuroinflammation, 2015, 12, 110.	3.1	72
365	Alternative kynurenic acid synthesis routes studied in the rat cerebellum. Frontiers in Cellular Neuroscience, 2015, 9, 178.	1.8	37

#	Article	IF	CITATIONS
366	Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology. Frontiers in Psychiatry, 2015, 6, 116.	1.3	105
367	Kynurenic Acid Content in Selected Culinary Herbs and Spices. Journal of Chemistry, 2015, 2015, 1-6.	0.9	21
368	Role of Tryptophan Metabolism in Mood, Behavior, and Cognition. , 2015, , 75-89.		3
369	Kynurenic Acid Is a Nutritional Cue that Enables Behavioral Plasticity. Cell, 2015, 160, 119-131.	13.5	57
370	Targeted plasma metabolome response to variations in dietary glycemic load in a randomized, controlled, crossover feeding trial in healthy adults. Food and Function, 2015, 6, 2949-2956.	2.1	43
371	Changing the Face of Kynurenines and Neurotoxicity: Therapeutic Considerations. International Journal of Molecular Sciences, 2015, 16, 9772-9793.	1.8	62
372	Current Neurological Observations and Complications of Dengue Virus Infection. Current Neurology and Neuroscience Reports, 2015, 15, 29.	2.0	26
373	Quinolinic acid/tryptophan ratios predict neurological disease in SIV-infected macaques and remain elevated in the brain under cART. Journal of NeuroVirology, 2015, 21, 449-463.	1.0	25
374	The kynurenine pathway and neurodegenerative disease. Seminars in Cell and Developmental Biology, 2015, 40, 134-141.	2.3	223
375	Indoleamine 2,3-dioxygenase is upregulated in the brain of rats with acute pancreatitis. Pancreatology, 2015, 15, 281-285.	0.5	3
376	Tryptophan and Nitric Oxide in Allergy. Molecular and Integrative Toxicology, 2015, , 55-73.	0.5	0
377	The Role of L-Tryptophan Kynurenine Pathway Metabolism in Various Infectious Diseases: Focus on Indoleamine 2,3-Dioxygenase 1. Molecular and Integrative Toxicology, 2015, , 95-120.	0.5	1
379	The role of the kynurenine pathway in suicidality in adolescent major depressive disorder. Psychiatry Research, 2015, 227, 206-212.	1.7	93
380	Central nervous system-specific alterations in the tryptophan metabolism in the 3-nitropropionic acid model of Huntington's disease. Pharmacology Biochemistry and Behavior, 2015, 132, 115-124.	1.3	20
381	Does Ketamine Have Anti-Suicidal Properties? Current Status and Future Directions. CNS Drugs, 2015, 29, 181-188.	2.7	39
382	Gene expression during zombie ant biting behavior reflects the complexity underlying fungal parasitic behavioral manipulation. BMC Genomics, 2015, 16, 620.	1.2	107
384	Role of Kynurenine Pathway in Aging. , 2015, , 63-74.		2
385	Targeting key dioxygenases in tryptophan–kynurenine metabolism for immunomodulation and cancer chemotherapy. Drug Discovery Today, 2015, 20, 609-617.	3.2	70

#	Article	IF	CITATIONS
386	A role for inflammatory metabolites as modulators of the glutamate N-methyl-d-aspartate receptor in depression and suicidality. Brain, Behavior, and Immunity, 2015, 43, 110-117.	2.0	240
387	Effects of Various Kynurenine Metabolites on Respiratory Parameters of Rat Brain, Liver and Heart Mitochondria. International Journal of Tryptophan Research, 2016, 9, IJTR.S37973.	1.0	21
388	Astrocytes as Pharmacological Targets in the Treatment of Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 423-443.	0.7	17
389	Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis. Frontiers in Immunology, 2016, 7, 246.	2.2	118
390	"WHAT'S BUGGING THE GUT IN OCD?à€•A REVIEW OF THE GUT MICROBIOME IN OBSESSIVE-COMPULSIVE DISORDER. Depression and Anxiety, 2016, 33, 171-178.	2.0	60
391	Cerebrospinal Fluid Biomarkers for Huntington's Disease. Journal of Huntington's Disease, 2016, 5, 1-13.	0.9	60
392	TDO as a therapeutic target in brain diseases. Metabolic Brain Disease, 2016, 31, 737-747.	1.4	32
393	Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5435-5440.	3.3	117
394	Tryptophan Metabolism in Allergic Disorders. International Archives of Allergy and Immunology, 2016, 169, 203-215.	0.9	64
395	Kynurenines and Glutamate. Advances in Pharmacology, 2016, 76, 13-37.	1.2	52
396	An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation. Translational Psychiatry, 2016, 6, e865-e865.	2.4	141
397	Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors. European Journal of Medicinal Chemistry, 2016, 123, 171-179.	2.6	30
398	A Nationwide Cohort Study of the Association Between Hospitalization With Infection and Risk of Death by Suicide. JAMA Psychiatry, 2016, 73, 912.	6.0	100
399	Non-Invasive, Focal Disconnection of Brain Circuitry Using Magnetic Resonance-Guided Low-Intensity Focused UltrasoundÂto Deliver a Neurotoxin. Ultrasound in Medicine and Biology, 2016, 42, 2261-2269.	0.7	13
400	Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian Chronic Kidney Disease pilot study. BMC Nephrology, 2016, 17, 171.	0.8	70
401	Changes in the levels of kynurenic acid and selected proinflammatory cytokines after pharmacological treatment and electroconvulsive therapy (ECT) in patients with depressive disorder. Current Problems of Psychiatry, 2016, 17, 75-82.	0.1	3
402	Central kynurenine pathway shift with age in women. Journal of Neurochemistry, 2016, 136, 995-1003.	2.1	60
403	Nitrobenzofurazan derivatives of N′-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1. European Journal of Medicinal Chemistry, 2016, 121, 364-375.	2.6	31

#	Article	IF	CITATIONS
404	Mechanisms of Inflammation-Associated Depression: Immune Influences on Tryptophan and Phenylalanine Metabolisms. Current Topics in Behavioral Neurosciences, 2016, 31, 95-115.	0.8	70
405	Quinolinic acid-immunoreactivity in the naÃ ⁻ ve mouse brain. Journal of Chemical Neuroanatomy, 2016, 71, 6-12.	1.0	6
406	Stable isotope dilution ultra-high performance liquid chromatography–tandem mass spectrometry quantitative profiling of tryptophan-related neuroactive substances in human serum and cerebrospinal fluid. Journal of Chromatography A, 2016, 1437, 145-157.	1.8	43
407	A metabolomics-based approach for ranking the depressive level in a chronic unpredictable mild stress rat model. RSC Advances, 2016, 6, 25751-25765.	1.7	5
408	Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms. Brain, Behavior, and Immunity, 2016, 51, 47-55.	2.0	56
409	Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. Neuropharmacology, 2017, 112, 373-388.	2.0	281
410	L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences. Neuropharmacology, 2017, 112, 264-274.	2.0	126
411	The kynurenine pathway and parasitic infections that affect CNS function. Neuropharmacology, 2017, 112, 389-398.	2.0	36
412	Kynurenine pathway metabolism and immune activation: Peripheral measurements in psychiatric and co-morbid conditions. Neuropharmacology, 2017, 112, 286-296.	2.0	62
413	Inflammatory markers in late pregnancy in association with postpartum depression—A nested case-control study. Psychoneuroendocrinology, 2017, 79, 146-159.	1.3	51
414	Identification and preliminary structure–activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 3780-3791.	1.4	13
415	Synthesis and evaluation of oxindoles as promising inhibitors of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1. MedChemComm, 2017, 8, 1640-1654.	3.5	13
416	Functional proteomic analysis of corticosteroid pharmacodynamics in rat liver: Relationship to hepatic stress, signaling, energy regulation, and drug metabolism. Journal of Proteomics, 2017, 160, 84-105.	1.2	22
417	Diverse Effects of Gut-Derived Serotonin in Intestinal Inflammation. ACS Chemical Neuroscience, 2017, 8, 920-931.	1.7	68
418	Ozonolysis of quinoline and quinoline derivatives in a Corning low flow reactor. Reaction Chemistry and Engineering, 2017, 2, 696-702.	1.9	12
419	Proposed biochemistry of Parkinson's and Alzheimer's diseases. Medical Hypotheses, 2017, 109, 131-138.	. 0.8	11
420	Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of L-4-chlorokynurenine in healthy volunteers. Scandinavian Journal of Pain, 2017, 17, 243-251.	0.5	23
421	Kynurenine 3-monooxygenase is implicated in antidepressants-responsive depressive-like behaviors and monoaminergic dysfunctions. Behavioural Brain Research, 2017, 317, 279-285.	1.2	24

#	Article	IF	CITATIONS
422	Excellent storage stability and sensitive detection of neurotoxin quinolinic acid. Biosensors and Bioelectronics, 2017, 90, 224-229.	5.3	15
423	Kynurenine Pathway in Autism Spectrum Disorders in Children. Neuropsychobiology, 2017, 76, 82-88.	0.9	46
424	Elevated Levels of Peripheral Kynurenine Decrease Bone Strength in Rats with Chronic Kidney Disease. Frontiers in Physiology, 2017, 8, 836.	1.3	34
425	The Relationships among Tryptophan, Kynurenine, Indoleamine 2,3-Dioxygenase, Depression, and Neuropsychological Performance. Frontiers in Psychology, 2017, 8, 1561.	1.1	58
426	Microglial Activation in the Pathogenesis of Huntington's Disease. Frontiers in Aging Neuroscience, 2017, 9, 193.	1.7	95
427	Increased Indoleamine 2,3-Dioxygenase and Quinolinic Acid Expression in Microglia and Müller Cells of Diabetic Human and Rodent Retina. , 2017, 58, 5043.		30
428	Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines. Journal of Alzheimer's Disease, 2018, 62, 523-547.	1.2	75
429	Modulation of Tryptophan and Serotonin Metabolism as a Biochemical Basis of the Behavioral Effects of Use and Withdrawal of Androgenic-Anabolic Steroids and Other Image- and Performance-Enhancing Agents. International Journal of Tryptophan Research, 2018, 11, 117864691775342.	1.0	17
430	Association of pre- and early post-transplant serum amino acids and metabolites of amino acids and liver transplant outcome. Transplant Immunology, 2018, 46, 42-48.	0.6	2
431	A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward. Journal of Huntington's Disease, 2018, 7, 109-135.	0.9	38
432	Phytochemical treatments target kynurenine pathway induced oxidative stress. Redox Report, 2018, 23, 25-28.	1.4	16
433	QPRTase modified N-doped carbon quantum dots: A fluorescent bioprobe for selective detection of neurotoxin quinolinic acid in human serum. Biosensors and Bioelectronics, 2018, 101, 103-109.	5.3	35
434	Neurological and Inflammatory Manifestations in Sjögren's Syndrome: The Role of the Kynurenine Metabolic Pathway. International Journal of Molecular Sciences, 2018, 19, 3953.	1.8	29
435	Tryptophan 2,3-dioxygenase inhibitory activities of tryptanthrin derivatives. European Journal of Medicinal Chemistry, 2018, 160, 133-145.	2.6	24
436	IL-18 Serum Levels and Variants of the Serotonin Transporter Gene Are Related to Awareness of Emotions in Healthy Subjects: A Preliminary Study. NeuroImmunoModulation, 2018, 25, 129-137.	0.9	4
437	Biofluid Biomarkers in Huntington's Disease. Methods in Molecular Biology, 2018, 1780, 329-396.	0.4	21
438	Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer. Frontiers in Immunology, 2018, 9, 1598.	2.2	31
439	Effect of wedelolactone and gallic acid on quinolinic acid-induced neurotoxicity and impaired motor function: significance to sporadic amyotrophic lateral sclerosis. NeuroToxicology, 2018, 68, 1-12.	1.4	22

#	Article	IF	CITATIONS
440	Resting-state connectivity and spontaneous activity of ventromedial prefrontal cortex predict depressive symptomology and peripheral inflammation in HIV. Journal of NeuroVirology, 2018, 24, 616-628.	1.0	15
441	Effect of Molecular Crowding Agents on the Activity and Stability of Immunosuppressive Enzyme Indoleamine 2,3â€Dioxygenase 1. ChemistrySelect, 2018, 3, 6294-6301.	0.7	3
442	Tryptophan and Kynurenine Metabolites: Are They Related to Depression?. Neuropsychobiology, 2019, 77, 23-28.	0.9	29
443	Traumatic Injury Leads to Inflammation and Altered Tryptophan Metabolism in the Juvenile Rabbit Brain. Journal of Neurotrauma, 2019, 36, 74-86.	1.7	26
444	Age―and diseaseâ€specific changes of the kynurenine pathway in Parkinson's and Alzheimer's disease. Journal of Neurochemistry, 2019, 151, 656-668.	2.1	81
445	Microorganisms, Tryptophan Metabolism, and Kynurenine Pathway: A Complex Interconnected Loop Influencing Human Health Status. International Journal of Tryptophan Research, 2019, 12, 117864691985299.	1.0	129
446	Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-AD Mice. Frontiers in Pharmacology, 2019, 10, 1044.	1.6	33
447	Kynurenines, Neuropsychiatric Symptoms, and Cognitive Prognosis in Patients with Mild Dementia. International Journal of Tryptophan Research, 2019, 12, 117864691987788.	1.0	13
448	Structural Basis of Inhibitor Selectivity in Human Indoleamine 2,3-Dioxygenase 1 and Tryptophan Dioxygenase. Journal of the American Chemical Society, 2019, 141, 18771-18779.	6.6	22
449	The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response. Molecular Psychiatry, 2021, 26, 4085-4095.	4.1	48
450	Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development. Frontiers in Pharmacology, 2019, 10, 840.	1.6	25
451	SCI and depression: Does inflammation commandeer the brain?. Experimental Neurology, 2019, 320, 112977.	2.0	14
452	A convenient route toward oneâ€pot multicomponent synthesis of spirochromenes and pyranopyrazoles accelerated via quinolinic acid. Journal of the Chinese Chemical Society, 2019, 66, 1721-1728.	0.8	9
453	Assessment of Prenatal Kynurenine Metabolism Using Tissue Slices: Focus on the Neosynthesis of Kynurenic Acid in Mice. Developmental Neuroscience, 2019, 41, 102-111.	1.0	19
454	Red-emitting gold nanoclusters for rapid fluorescence sensing of tryptophan metabolites. Sensors and Actuators B: Chemical, 2019, 288, 728-733.	4.0	37
455	Metabolomics Approaches for the Diagnosis and Understanding of Kidney Diseases. Metabolites, 2019, 9, 34.	1.3	60
456	Modulation of Enzyme Activity in the Kynurenine Pathway by Kynurenine Monooxygenase Inhibition. Frontiers in Molecular Biosciences, 2019, 6, 3.	1.6	32
457	Fluid and imaging biomarkers for Huntington's disease. Molecular and Cellular Neurosciences, 2019, 97, 67-80.	1.0	41

#	Article	IF	CITATIONS
458	H2S suppresses indoleamine 2, 3-dioxygenase 1 and exhibits immunotherapeutic efficacy in murine hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 88.	3.5	19
459	Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation. Nature Immunology, 2019, 20, 50-63.	7.0	304
460	Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington's disease. Expert Opinion on Therapeutic Targets, 2019, 23, 39-51.	1.5	15
461	Neuroprotective Effect of Myxobacterial Extracts on Quinolinic Acid-Induced Toxicity in Primary Human Neurons. Neurotoxicity Research, 2019, 35, 281-290.	1.3	9
462	Metabolites Associated With Risk of Developing Mobility Disability in the Health, Aging and Body Composition Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 73-80.	1.7	12
463	Spectroscopic (IR, Raman, NMR), thermal and theoretical (DFT) study of alkali metal dipicolinates (2,6) and quinolinates (2,3). Arabian Journal of Chemistry, 2019, 12, 4414-4426.	2.3	5
464	Inflammatory markers in women with postpartum depressive symptoms. Journal of Neuroscience Research, 2020, 98, 1309-1321.	1.3	43
465	Tryptophan in health and disease. Advances in Clinical Chemistry, 2020, 95, 165-218.	1.8	150
466	Elevated quinolinic acid levels in cerebrospinal fluid in subacute sclerosing panencephalitis. Journal of Neuroimmunology, 2020, 339, 577088.	1.1	10
467	Structural and Functional Characterization of the Gut Microbiota in Elderly Women With Migraine. Frontiers in Cellular and Infection Microbiology, 2019, 9, 470.	1.8	43
468	Kynurenine Pathway in Chronic Kidney Disease: What's Old, What's New, and What's Next?. International Journal of Tryptophan Research, 2020, 13, 117864692095488.	1.0	31
469	Immune Activation and Anemia Are Associated with Decreased Quality of Life in Patients with Solid Tumors. Journal of Clinical Medicine, 2020, 9, 3248.	1.0	5
470	Blood-based kynurenine pathway alterations in schizophrenia spectrum disorders: A meta-analysis. Schizophrenia Research, 2020, 223, 43-52.	1.1	20
471	Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401. International Journal of Molecular Sciences, 2020, 21, 5979.	1.8	6
472	Nutritional Therapy to Modulate Tryptophan Metabolism and Aryl Hydrocarbon-Receptor Signaling Activation in Human Diseases. Nutrients, 2020, 12, 2846.	1.7	35
473	Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway. International Journal of Molecular Sciences, 2020, 21, 9338.	1.8	78
474	Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion. British Journal of Cancer, 2020, 123, 137-147.	2.9	17
475	Tryptophan Metabolic Pathways Are Altered in Obesity and Are Associated With Systemic Inflammation. Frontiers in Immunology, 2020, 11, 557.	2.2	105

	CITATION	Report	
#	Article	IF	CITATIONS
476	Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum. Neurochemical Research, 2020, 45, 1191-1201.	1.6	12
477	Serum Metabolic Profiles of the Tryptophan-Kynurenine Pathway in the high risk subjects of major depressive disorder. Scientific Reports, 2020, 10, 1961.	1.6	44
478	Homeostasis Imbalance of Microglia and Astrocytes Leads to Alteration in the Metabolites of the Kynurenine Pathway in LPS-Induced Depressive-Like Mice. International Journal of Molecular Sciences, 2020, 21, 1460.	1.8	29
479	Vitamin D receptor promotes healthy microbial metabolites and microbiome. Scientific Reports, 2020, 10, 7340.	1.6	47
480	Kynurenic Acid Levels are Increased in the CSF of Alzheimer's Disease Patients. Biomolecules, 2020, 10, 571.	1.8	37
481	Reductions in anti-inflammatory gut bacteria are associated with depression in a sample of young adults. Brain, Behavior, and Immunity, 2020, 88, 308-324.	2.0	115
482	Treatment With Lipopolysaccharide Induces Distinct Changes in Metabolite Profile and Body Weight in 129Sv and Bl6 Mouse Strains. Frontiers in Pharmacology, 2020, 11, 371.	1.6	12
483	Large-Scale Multi-omic Analysis of COVID-19 Severity. Cell Systems, 2021, 12, 23-40.e7.	2.9	438
484	Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid. International Journal of Molecular Sciences, 2021, 22, 403.	1.8	39
485	Endogenous Kynurenic Acid and Neurotoxicity. , 2021, , 1-31.		1
486	Increased serum QUIN/KYNA is a reliable biomarker of post-stroke cognitive decline. Molecular Neurodegeneration, 2021, 16, 7.	4.4	16
487	Blockade of Indoleamine 2, 3-dioxygenase 1 ameliorates hippocampal neurogenesis and BOLD-fMRI signals in chronic stress precipitated depression. Aging, 2021, 13, 5875-5891.	1.4	17
488	Effect of dural inflammatory soup application on activation and sensitization markers in the caudal trigeminal nucleus of the rat and the modulatory effects of sumatriptan and kynurenic acid. Journal of Headache and Pain, 2021, 22, 17.	2.5	21
489	The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. European Journal of Pharmacology, 2021, 896, 173921.	1.7	57
490	A multi-modal data harmonisation approach for discovery of COVID-19 drug targets. Briefings in Bioinformatics, 2021, 22, .	3.2	13
491	Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease. Journal of Neurochemistry, 2021, 158, 539-553.	2.1	18
492	Kynurenines as a Novel Target for the Treatment of Malignancies. Pharmaceuticals, 2021, 14, 606.	1.7	18
493	Comprehensive Bibliometric Analysis of the Kynurenine Pathway in Mood Disorders: Focus on Gut Microbiota Research. Frontiers in Pharmacology, 2021, 12, 687757.	1.6	27

#	Article	IF	CITATIONS
494	Role of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders. Cells, 2021, 10, 1603.	1.8	53
495	Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy—Kynurenines Are Important Players. Molecules, 2021, 26, 3423.	1.7	20
496	Vitamin C and E Treatment Blocks Changes in Kynurenine Metabolism Triggered by Three Weeks of Sprint Interval Training in Recreationally Active Elderly Humans. Antioxidants, 2021, 10, 1443.	2.2	1
497	Increase of Kynurenic Acid after Encephalomyocarditis Virus Infection and Its Significances. NeuroSignals, 2021, 29, 24-34.	0.5	0
498	Inflammatory cytokines, cognition, and response to antidepressant treatment in patients with major depressive disorder. Psychiatry Research, 2021, 305, 114202.	1.7	8
499	Anatomical and neurochemical organization of the serotonergic system in the mammalian brain and in particular the involvement of the dorsal raphe nucleus in relation to neurological diseases. Progress in Brain Research, 2021, 261, 41-81.	0.9	15
500	Cerebrospinal fluid metabolomics: detection of neuroinflammation in human central nervous system disease. Clinical and Translational Immunology, 2021, 10, e1318.	1.7	30
501	Kynurenines in Neurodegenerative Disorders: Therapeutic Consideration. Advances in Experimental Medicine and Biology, 2004, 541, 169-183.	0.8	29
502	The Kynurenine Pathway and Neurologic Disease. Advances in Experimental Medicine and Biology, 1996, 398, 125-129.	0.8	35
503	Activated Cellular Immunity and Decreased Serum Tryptophan in Healthy Pregnancy. Advances in Experimental Medicine and Biology, 1996, 398, 149-153.	0.8	11
504	Cytokine and Drug Modulation of Kynurenine Pathway Metabolism by Blood Mononuclear Cells. Advances in Experimental Medicine and Biology, 1996, 398, 161-165.	0.8	13
505	The Effects of Induced Kynurenine Pathway on Immunocytochemical Changes in Rat Tissues Following Excessive L-Tryptophan Consumption. Advances in Experimental Medicine and Biology, 1996, 398, 177-182.	0.8	10
506	Brain Tryptophan. Advances in Experimental Medicine and Biology, 1996, , 27-34.	0.8	13
507	Regulation Of Quinolinic Acid in the Normal Rat Brain by Kynurenine Pathway Precursors. Advances in Experimental Medicine and Biology, 1996, 398, 229-239.	0.8	12
508	4-Chloro-3-Hydroxyanthranilate Attenuate Quinolinic Acid Accumulation in Brain Following Transient Cerebral Ischemia in the Gerbil. Advances in Experimental Medicine and Biology, 1996, 398, 407-411.	0.8	5
509	Kynurenine Pathway Metabolism in the Galactosamine Model of Hepatic Injury. Advances in Experimental Medicine and Biology, 1996, 398, 421-424.	0.8	1
510	Kynurenine Pathway Enzymes in Brain. Advances in Experimental Medicine and Biology, 1996, , 485-492.	0.8	24
511	Endogenous Kynurenic Acid and Neurotoxicity. , 2014, , 421-453.		5

#	Article	IF	CITATIONS
512	Neurokynurenines - Seizures or/and Anxiety in Children With Epilepsy ?. Advances in Experimental Medicine and Biology, 2003, 527, 191-195.	0.8	2
513	Tryptophan Metabolism Along the Kynurenine Pathway in Rats. Advances in Experimental Medicine and Biology, 2003, 527, 481-496.	0.8	8
514	Kynurenine Pathway Metabolism in Human Astrocytes. Advances in Experimental Medicine and Biology, 1999, 467, 125-131.	0.8	33
515	Degradation of Tryptophan in Neurodegenerative Disorders. Advances in Experimental Medicine and Biology, 1999, 467, 133-138.	0.8	55
516	Pet Studies of Serotonin Synthesis in the Human Brain. Advances in Experimental Medicine and Biology, 1999, 467, 11-18.	0.8	21
517	Labeled Kynurenine Pharmacokinetic Modeling Studies in Gerbils. Advances in Experimental Medicine and Biology, 1999, 467, 315-320.	0.8	2
518	Tryptophan Toxicity—Time and Dose Response in Rats. Advances in Experimental Medicine and Biology, 1999, , 507-516.	0.8	20
519	Antioxidant Activities and Redox Regulation of Interferon-Gamma-Induced Tryptophan Metabolism in Human Monocytes and Macrophages. Advances in Experimental Medicine and Biology, 1999, 467, 541-552.	0.8	24
520	The Role of the Kynurenine Pathway in Neurodegenerative Diseases. , 2015, , 193-204.		1
521	Serotonin-Immune Interactions in Major Depression. Research and Perspectives in Neurosciences, 2000, , 79-87.	0.4	8
522	Measurement of neopterin, kynurenine and tryptophan in sera of schizophrenic patients. Key Topics in Brain Research, 1999, , 115-119.	0.2	22
523	Neural Transplantation in Huntington's Disease. , 2007, , 417-437.		2
524	Cerebrospinal Fluid. , 1997, , 785-827.		13
525	Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes Journal of Biological Chemistry, 1994, 269, 14457-14464.	1.6	183
526	Molecular cloning and functional expression of human 3-hydroxyanthranilic-acid dioxygenase Journal of Biological Chemistry, 1994, 269, 13792-13797.	1.6	60
527	A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. Journal of Biological Chemistry, 1993, 268, 15496-15503.	1.6	159
528	Conformational Plasticity in Human Heme-Based Dioxygenases. Journal of the American Chemical Society, 2021, 143, 1836-1845.	6.6	11
529	Quinolinic acid in the cerebrospinal fluid of children after traumatic brain injury. Critical Care Medicine, 1999, 27, 493-497.	0.4	56

#	Article	IF	CITATIONS
531	Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains Journal of Clinical Investigation, 1993, 91, 2769-2775.	3.9	190
532	Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. Journal of Clinical Investigation, 2008, 118, 2661-9.	3.9	125
533	Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. Journal of Clinical Investigation, 2012, 122, 2940-2954.	3.9	269
534	The Effect of Tryptophan 2,3-Dioxygenase Inhibition on Kynurenine Metabolism and Cognitive Function in the APP23 Mouse Model of Alzheimer's Disease. International Journal of Tryptophan Research, 2020, 13, 117864692097265.	1.0	10
535	Combined inhibition of indoleamine 2,3-dioxygenase and nitric oxide synthase modulates neurotoxin release by interferon-Î ³ -activated macrophages. Journal of Leukocyte Biology, 2000, 68, 260-266.	1.5	29
536	Kynurenic Acid in Brain and Cerebrospinal Fluid of Fetal, Newborn, and Adult Sheep and Effects of Placental Embolization. Pediatric Research, 1999, 45, 820-826.	1.1	30
537	The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons. PLoS ONE, 2009, 4, e6344.	1.1	179
538	Fatigue in Patients with Lung Cancer Is Related with Accelerated Tryptophan Breakdown. PLoS ONE, 2012, 7, e36956.	1.1	32
539	Activated Immune System and Inflammation in Healthy Ageing: Relevance for Tryptophan and Neopterin Metabolism. Current Pharmaceutical Design, 2014, 20, 6048-6057.	0.9	58
540	Urinary Metabolomics Reveals Alterations of Aromatic Amino Acid Metabolism of Alzheimer's Disease in the Transgenic CRND8 Mice. Current Alzheimer Research, 2016, 13, 764-776.	0.7	25
541	Inflammation and Mood Disorders: Proinflammatory Cytokines and the Pathogenesis of Depression. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2010, 9, 212-220.	1.1	16
542	The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders–relation to drug treatment. Dialogues in Clinical Neuroscience, 2009, 11, 319-332.	1.8	64
543	T. gondii Infection Acquired during Pregnancy and/or after Birth may be Responsible for Development of both Type 1 and 2 Diabetes Mellitus. Journal of Diabetes & Metabolism, 2013, 04, .	0.2	12
544	A link between central kynurenine metabolism and bone strength in rats with chronic kidney disease. PeerJ, 2017, 5, e3199.	0.9	7
545	Differentiation of viral and autoimmune central nervous system inflammation by kynurenine pathway. Annals of Clinical and Translational Neurology, 2021, 8, 2228-2234.	1.7	4
546	Markers of Excitotoxicity in Patients: Tool for Diagnosis or Therapy?. , 2004, , 317-337.		0
547	Integrative hypothesis for Huntington's disease: a brief review on experimental evidence Physiological Research, 2007, 56, 513-526.	0.4	42
548	Protein Misfolding, Mitochondrial Disturbances, And Kynurenines In The Pathogenesis Of Neurodegenerative Disorders. , 2009, , 452-472.		0

#	Article	IF	CITATIONS
549	Entzündliche Veräderungen als gemeinsame Pathogenese affektiver und schizophrener Erkrankungen. , 2010, , 59-91.		0
550	Immunologie und Infektionskrankheiten. , 2010, , 323-417.		0
551	Interaction Between Inflammatory State and Neurochemical Changes in Major Psychiatric Disorders. , 0, , .		0
552	Psychiatric Disorders - Worldwide Advances. , 2011, , .		1
553	CHAPTER 14. Tryptophan Metabolism in Parkinson's Disease: Future Therapeutic Possibilities. RSC Drug Discovery Series, 2013, , 327-340.	0.2	0
554	Urinary Organic Acids Profiling for Assessment of Functional Nutrient Deficiencies, Gut Dysbiosis, and Toxicity. , 2013, , 224-233.		0
555	Immuno-modulatory Role of Indoleamine 2, 3-Dioxygenase in Allogeneic Islet and Skin Transplantation. Research in Immunology an International Journal, 0, , 1-17.	0.0	2
556	Stroke Patients after repetitive Transcranial Magnetic Stimulation (rTMS)–Alterations of Tryptophan Metabolites in the Serum. International Journal of Neurorehabilitation, 2014, 01, .	0.1	5
557	Quinolinate and Related Excitotoxins: Mechanisms of Neurotoxicity and Disease Relevance. , 2014, , 1543-1565.		0
558	Role of Tetrahydrobiopterin in Cytokine-Stimulated Metabolism of Tryptophan and Hydroxylation of Arginine. Advances in Experimental Medicine and Biology, 1993, 338, 289-294.	0.8	2
559	Quantification of Quinolinic Acid Metabolism by Macrophages and Astrocytes. , 1995, , 317-325.		0
560	Huntington's Disease. , 1996, , 323-342.		0
561	Tyrosine and Tryptophan Derivatives in Pig Lumbar Cerebrospinal Fluid. Advances in Experimental Medicine and Biology, 1996, 398, 119-121.	0.8	0
562	Endogenous Kynurenine Derivatives and Pain. Advances in Experimental Medicine and Biology, 1996, 398, 83-87.	0.8	1
563	Oxidative damage in rat skeletal muscle after excessive L-tryptophan and atherogenic diets. , 1998, , 257-271.		1
564	Sources of the neurotoxin quinolinic acid in the brain of HIVâ€1â€infected patients and retrovirusâ€infected macaques. FASEB Journal, 1998, 12, 881-896.	0.2	21
565	Inducible NOS and Other Novel Mediators of Inflammation in Brain Trauma. , 1999, , 145-161.		0
566	Cerebrospinal Fluid Markers in the Management of Central Nervous System HIV Infection and the AIDS Dementia Complex. , 0, , 173-179.		0

CITA	TION	DEDOI	ЪΤ
CITA	TUN	REPUI	τι.

#	Article	IF	CITATIONS
568	Metabolic Alterations Amalgamated with Huntingtonâ \in ${}^{\mathrm{Ms}}$ s Disease. , 2019, , 163-183.		0
570	Neocortical Epilepsy. , 2005, , 123-129.		0
572	Labelled alpha-methyl-L-tryptophan as a tracer for the study of the brain serotonergic system. Journal of Psychiatry and Neuroscience, 2001, 26, 293-303.	1.4	22
573	The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. Journal of Psychiatry and Neuroscience, 2004, 29, 11-7.	1.4	174
574	Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria. American Journal of Pathology, 1998, 152, 611-9.	1.9	137
575	Expression of inflammatory cytokines and inducible nitric oxide synthase in brains of SIV-infected rhesus monkeys: applications to HIV-induced central nervous system disease. Molecular Medicine, 1996, 2, 27-37.	1.9	32
576	Protective Effect of Safranal, a Constituent of Crocus sativus, on Quinolinic Acid-induced Oxidative Damage in Rat Hippocampus. Iranian Journal of Basic Medical Sciences, 2013, 16, 73-82.	1.0	68
577	Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer's disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity. Journal of Geriatric Care and Research, 2018, 5, 57-67.	1.0	4
578	Elucidation of the Central Serotonin Metabolism Pathway in Rhesus Macaques (<i>Macaca) Tj ETQq0 0 0 rgBT /</i>	Overlgck]	10 Tf 50 422 T
579	Brain Kynurenine Pathway and Functional Outcome of Rats Resuscitated From Cardiac Arrest. Journal of the American Heart Association, 2021, 10, e021071.	1.6	2
580	Kynurenic acid in neurodegenerative disorders—unique neuroprotection or doubleâ€edged sword?. CNS Neuroscience and Therapeutics, 2022, 28, 19-35.	1.9	38
581	The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors. Molecules, 2022, 27, 273.	1.7	24
583	Cellular Localization of Kynurenine 3-Monooxygenase in the Brain: Challenging the Dogma. Antioxidants, 2022, 11, 315.	2.2	7
584	Kynurenine Metabolism and Alzheimer's Disease: The Potential Targets and Approaches. Neurochemical Research, 2022, 47, 1459-1476.	1.6	13
585	Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics. Current Topics in Behavioral Neurosciences, 2022, , 141-167.	0.8	4
586	Kynurenine-3-monooxygenase (KMO) broadly inhibits viral infections via triggering NMDAR/Ca2+ influx and CaMKII/ IRF3-mediated IFN-I ² production. PLoS Pathogens, 2022, 18, e1010366.	2.1	10
587	Molecular Pathogenesis for Schizophrenia and Major Depression. , 2008, , 511-530.		0
599	Migraine signaling pathways: amino acid metabolites that regulate migraine and predispose migraineurs to headache. Molecular and Cellular Biochemistry, 2022, , 1.	1.4	0

#	Article	IF	CITATIONS
600	Abnormal Activation of Tryptophan-Kynurenine Pathway in Women With Polycystic Ovary Syndrome. Frontiers in Endocrinology, 2022, 13, .	1.5	6
601	Multi-strain Probiotic Formulation Reverses Maternal Separation and Chronic Unpredictable Mild Stress-Generated Anxiety- and Depression-like Phenotypes by Modulating Gut Microbiome–Brain Activity in Rats. ACS Chemical Neuroscience, 2022, 13, 1948-1965.	1.7	31
602	Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression. Journal of Neuroinflammation, 2022, 19, .	3.1	119
603	The Footprint of Kynurenine Pathway in Cardiovascular Diseases. International Journal of Tryptophan Research, 2022, 15, 117864692210966.	1.0	19
604	Peridontitis as a Risk Factor for Attention Deficit Hyperactivity Disorder: Possible Neuro-inflammatory Mechanisms. Neurochemical Research, 2022, 47, 2925-2935.	1.6	5
605	The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Clutamate, Quinolinic Acid, and Gentamicin. Pharmaceuticals, 2022, 15, 882.	1.7	6
606	NEUROLOGIC AND PSYCHIATRIC MANIFESTATIONS OF PEDIATRIC AIDS. Immunology and Allergy Clinics of North America, 1995, 15, 285-305.	0.7	1
607	Inflammatory cytokines and mechanical injury induce post-traumatic osteoarthritis-like changes in a human cartilage-bone-synovium microphysiological system. Arthritis Research and Therapy, 2022, 24, .	1.6	16
608	Peripheral Interleukin-18 is negatively correlated with abnormal brain activity in patients with depression: a resting-state fMRI study. BMC Psychiatry, 2022, 22, .	1.1	9
609	Binge-like mephedrone treatment induces memory impairment concomitant with brain kynurenic acid reduction in mice. Toxicology and Applied Pharmacology, 2022, 454, 116216.	1.3	2
610	Prophylactic and Therapeutic Effect of Kynurenine for Experimental Autoimmune Encephalomyelitis (EAE) Disease. International Journal of Tryptophan Research, 2022, 15, 117864692211186.	1.0	1
611	The Involvement of Kynurenine Pathway in Neurodegenerative Diseases. Current Neuropharmacology, 2023, 21, 260-272.	1.4	4
612	Impact of a High-Fat Diet on the Metabolomics Profile of 129S6 and C57BL6 Mouse Strains. International Journal of Molecular Sciences, 2022, 23, 11682.	1.8	0
613	Cluster Analysis Statistical Spectroscopy for the Identification of Metabolites in 1H NMR Metabolomics. Metabolites, 2022, 12, 992.	1.3	2
614	Target Metabolites to Slow Down Progression of Amyotrophic Lateral Sclerosis in Mice. Metabolites, 2022, 12, 1253.	1.3	4
615	Endogenous Kynurenic Acid and Neurotoxicity. , 2022, , 1035-1065.		0
616	Sex Differences in Tryptophan Metabolism: A Systematic Review Focused on Neuropsychiatric Disorders. International Journal of Molecular Sciences, 2023, 24, 6010.	1.8	5
617	Synthesis, In Silico, In Vivo, and Ex Vivo Evaluation of a Boron-Containing Quinolinate Derivative with Presumptive Action on mGluRs. Inorganics, 2023, 11, 94.	1.2	2

#	Article	IF	CITATIONS
618	Stress and Kynurenine-Inflammation Pathway in Major Depressive Disorder. Advances in Experimental Medicine and Biology, 2023, , 163-190.	0.8	0
624	Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	23
627	Cerebrospinal Fluid Biomarkers in Huntington's Disease. Contemporary Clinical Neuroscience, 2023, , 19-44.	0.3	0